{"id":5289,"date":"2009-02-09T22:40:26","date_gmt":"2009-02-09T21:40:26","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=5289"},"modified":"2013-08-16T15:07:09","modified_gmt":"2013-08-16T15:07:09","slug":"serum-bilirubin-increases-when-peg-interferon-and-ribavirin-are-used-with-atazanavir","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/5289","title":{"rendered":"Serum bilirubin increases when PEG-interferon and ribavirin are used with atazanavir"},"content":{"rendered":"<p><strong><a href=\"http:\/\/www.hiv-druginteractions.org\/\">http:\/\/www.hiv-druginteractions.org<\/a><\/strong><\/p>\n<p><strong>This was a retrospective study of 72 HCV\/HIV co-infected patients who initiated HCV therapy (peg-IFN weekly and ribavirin 1000-1200 mg\/day) and were on either an atazanavir-containing regimen (n=36) or other antiretrovirals (not including indinavir, n=36). Fourteen subjects in the atazanavir group and six in the control group were then excluded from analysis due to poor drug adherence.<\/strong><\/p>\n<p>The major finding was that on average serum bilirubin increases following initiation of peg-IFN and ribavirin were 1.9-fold higher in patients on atazanavir than in controls. In the atazanavir group, the proportion of patients with grade 3-4 hyperbilirubinaemia increased from 2\/22 to 10\/22 after beginning hepatitis therapy. No controls developed hyperbilirubinaemia.<\/p>\n<p>The elevation in serum bilirubin levels is directly related to the haemoglobin decline as a result of ribavirin use and haemolysis.<\/p>\n<p>The clearance of the increased bilirubin is compromised by atazanavir.<\/p>\n<p>Reference:<\/p>\n<p>Rodriguez-Novoa S et al. Increase in serum bilirubin in HIV\/hepatitis-C virus co-infected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS, 2008, 22(18): 2535-2548.<br \/>\n<a href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19005277\">http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19005277<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>http:\/\/www.hiv-druginteractions.org This was a retrospective study of 72 HCV\/HIV co-infected patients who initiated HCV therapy (peg-IFN weekly and ribavirin 1000-1200 mg\/day) and were on either an atazanavir-containing regimen (n=36) or other antiretrovirals (not including indinavir, n=36). Fourteen subjects in the &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[],"class_list":["post-5289","post","type-post","status-publish","format-standard","hentry","category-pk-and-drug-interactions"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5289","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=5289"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/5289\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=5289"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=5289"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=5289"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}